ArticleTobacco induced diseases2026
Association between urinary NNAL concentrations and osteoarthritis: Evidence from NHANES 2007-2012.
Article in Tobacco induced diseases, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
6 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
introductionOsteoarthritis (OA) is the most prevalent degenerative joint disorder globally, yet the impact of smoking on its development remains contentious. The compound 4-(methylnitrosamino)-1-(3-pyridyl)-1-butanol (NNAL), a principal metabolite of the tobacco-specific nitrosamine 4-(methylnitrosamino)-1-(3-pyridyl)-1-butanone (NNK), is a well-recognized biomarker for smoking exposure. This study aimed to use urinary NNAL as a biomarker to evaluate the association between tobacco exposure and OA.
methodsThis study was a secondary cross-sectional analysis of pooled data from the 2007-2012 cycles of the National Health and Nutrition Examination Survey (NHANES), including 10848 adults. OA was assessed using self-reported physician diagnosis and radiographic examination, with a Kellgren-Lawrence grade ≥2 indicating radiographic OA; urinary NNAL concentration was used as the biomarker of tobacco exposure. Survey-weighted multivariable logistic regression analysis and subgroup analyses were performed after adjusting for confounding factors.
resultsElevated urinary NNAL concentrations were positively associated with greater odds of OA. In the fully adjusted model, urinary NNAL concentrations >0.077925 ng/mL were associated with greater odds of OA (adjusted odds ratio, AOR=1.55; 95% CI: 1.36-1.76). Evidence of interaction was observed for age (p for interaction <0.001), but not for sex (p=0.231) or BMI (p=0.127). Among adults aged <60 years, the AOR for the highest versus lowest NNAL category was 1.69 (95% CI: 1.46-1.95), whereas the corresponding AOR was 0.98 (95% CI: 0.82-1.17) among adults aged ≥60 years.
conclusionsHigher urinary NNAL was associated with an increased likelihood of OA, with more prominent effects observed in middle-aged adults. Given the cross-sectional design, temporality and causality cannot be established, and the potential association requires confirmation in longitudinal and mechanistic studies.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.